LAUSR

Cardiovascular disease and cancer are the two leading causes of morbidity and mortality in the world. The emerging field of cardio-oncology has revealed that these seemingly disparate disease processes are intertwined, owing to the cardiovascular sequelae of anticancer therapies, shared risk factors that predispose individuals to both cardiovascular disease and cancer, as well the possible potentiation of cancer growth by cardiac dysfunction. As a result, interest has increased in understanding the fundamental biological mechanisms that are central to the relationship between cardiovascular disease and cancer. Metabolism, appropriate regulation of energy, energy substrate utilization, and macromolecular synthesis and breakdown are fundamental processes for cellular and organismal survival. In this Review, we explore the emerging data identifying metabolic dysregulation as an important theme in cardio-oncology. We discuss the growing recognition of metabolic reprogramming in cardiovascular disease and cancer and view the novel area of cardio-oncology through the lens of metabolism. In this Review, the authors explore metabolic dysregulation as an important theme in cardio-oncology. They discuss metabolic reprogramming in cardiovascular disease and cancer and the possibility that therapeutically targeting metabolic and immunometabolic changes in patients with cancer might also reduce their risk of cardiovascular disease. Metabolic remodelling is a defining feature of both cardiovascular diseases and tumours. Metabolic dysregulation of cancer cells extends beyond the tumour microenvironment and can lead to both systemic and cardiac-specific consequences. Cardiovascular disease and cancer share several risk factors, including diabetes mellitus, dyslipidaemia, cachexia and an impaired immune response. Anticancer therapies can result in adverse cardiac events, including acute myocardial infarction and heart failure. Targeting metabolic features of cancer cells might limit tumour growth and also protect the heart against adverse remodelling. Metabolic remodelling is a defining feature of both cardiovascular diseases and tumours. Metabolic dysregulation of cancer cells extends beyond the tumour microenvironment and can lead to both systemic and cardiac-specific consequences. Cardiovascular disease and cancer share several risk factors, including diabetes mellitus, dyslipidaemia, cachexia and an impaired immune response. Anticancer therapies can result in adverse cardiac events, including acute myocardial infarction and heart failure. Targeting metabolic features of cancer cells might limit tumour growth and also protect the heart against adverse remodelling.